Pharming Group N.V. announced that an abstract was presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in San Francisco, CA.
Additionally, Pharming is pleased to announce sponsorship of the AAAAI Foundation Michael M. Frank, MD, FAAAAI Lectureship.
The presentation Recombinant Human C1 Esterase Inhibitor as Short-Term Prophylaxis for Dental Procedures in Patients with Hereditary Angioedema: A Case Series by Anna Valerieva, MD, PhD et al. described a retrospective study in patients diagnosed with hereditary angioedema (HAE) from Europe and the United States who received RUCONEST® (C1 esterase inhibitor [recombinant]) prior to dental procedures to prevent an HAE attack. The authors concluded that short-term prophylaxis with RUCONEST®, administered within approximately 60 minutes before the procedure, was efficacious and safe in adults and reduced the risk of an attack post-procedure. The presentation may be viewed at https://synchronymed.com/smc-assets/AAAAI2019Poster111.pdf
Pharming also announces sponsorship of one of the AAAAI Foundation 5-year named lectureships which provide funding for research that leads to the prevention and cure of asthma, allergic and immunologic diseases. This year, the AAAAI Foundation is pleased to honor the life work of Dr. Michael Frank with the creation of theMichael M. Frank, MD FAAAAI Lectureship.
“Michael Frank has devoted his career to help improve the lives of HAE patients which makes him a perfect recipient of this lectureship”, stated Jonathan Bernstein, MD, FAAAI—Lectureships and Major Gifts Chair AAAAI Foundation. “We are grateful to Pharming for their support in helping to establish the Michael Frank lectureship”.
The above mentioned presentation and complete pressrelease are available on Pharming’s website www.pharming.com.